New Wave of Kidney Disease Treatments Shows Real Promise

For people with IgA nephropathy, the most common kidney disease in the world, hope has arrived in the form of multiple breakthrough treatments approved in just the past two years.

The disease affects at least 2.5 per 100,000 people globally and can lead to kidney failure within 10 to 20 years for up to half of patients. Until recently, treatment options were extremely limited.

"Now we have drugs that can slow or halt that progression, and this is just the first wave of therapies," said Dr. Brad Rovin, director of nephrology at Ohio State University. He presented research at the National Kidney Foundation's 2026 Spring Clinical Meetings, where IgA nephropathy dominated the conversation.

Five new treatments have received FDA approval since 2023, each targeting different parts of how the disease develops. The latest study shows one drug called iptacopan slowed kidney function decline by more than 57% compared to standard care over two years.

Another treatment, sibeprenlimab, reduced protein in urine by more than 51% in just nine months. This matters because protein in urine signals kidney damage, and reducing it helps preserve kidney function longer.

Scientists finally understand what causes the disease after years of research. The body produces faulty antibodies that attack the kidneys' filtering system. The new drugs target these antibodies at different stages, giving doctors multiple tools to help patients.

An FDA framework created in 2019 helped speed up approvals by allowing drugs to be tested using faster measures of success. This cleared the path for multiple companies to develop treatments simultaneously.

The Ripple Effect spreads beyond just having more options. With several effective drugs now available, doctors can start personalizing treatment for each patient based on their specific disease pattern. "This really makes IgA nephropathy one of the hottest therapeutic fields," Rovin said. "It allows us to now start thinking about precision medicine."

More treatments are already in clinical trials and expected to arrive in coming months. For the millions of people living with this disease worldwide, the message is clear: kidney failure is no longer inevitable.

The research presented at the National Kidney Foundation meeting showed consistent safety across all the new treatments, with side effects manageable for most patients. No deaths occurred in the major trials.

This wave of progress represents what can happen when scientists understand a disease at the molecular level and regulators create pathways to bring treatments to patients faster.